306 related articles for article (PubMed ID: 19943106)
1. Cardiomyopathy in Duchenne muscular dystrophy: pathogenesis and therapeutics.
Fayssoil A; Nardi O; Orlikowski D; Annane D
Heart Fail Rev; 2010 Jan; 15(1):103-7. PubMed ID: 19943106
[TBL] [Abstract][Full Text] [Related]
2. Cardiac consequences to skeletal muscle-centric therapeutics for Duchenne muscular dystrophy.
Townsend D; Yasuda S; Chamberlain J; Metzger JM
Trends Cardiovasc Med; 2009 Feb; 19(2):50-55. PubMed ID: 19577712
[TBL] [Abstract][Full Text] [Related]
3. Dystrophin-Deficient Cardiomyopathy.
Kamdar F; Garry DJ
J Am Coll Cardiol; 2016 May; 67(21):2533-46. PubMed ID: 27230049
[TBL] [Abstract][Full Text] [Related]
4. Cardiac Involvement in Duchenne Muscular Dystrophy and Related Dystrophinopathies.
Mavrogeni SI; Markousis-Mavrogenis G; Papavasiliou A; Papadopoulos G; Kolovou G
Methods Mol Biol; 2018; 1687():31-42. PubMed ID: 29067654
[TBL] [Abstract][Full Text] [Related]
5. [Management of myocardial damage in muscular dystrophy].
Tamura T
Brain Nerve; 2011 Nov; 63(11):1217-28. PubMed ID: 22068474
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological management of dilated cardiomyopathy in Duchenne muscular dystrophy: A systematic review.
Haddad CN; Ali S; Stephanou D; Assakura MS; Sahagian L; Trogkanis E
Hellenic J Cardiol; 2023; 74():58-64. PubMed ID: 37406964
[TBL] [Abstract][Full Text] [Related]
7. Micro-dystrophin gene therapy prevents heart failure in an improved Duchenne muscular dystrophy cardiomyopathy mouse model.
Howard ZM; Dorn LE; Lowe J; Gertzen MD; Ciccone P; Rastogi N; Odom GL; Accornero F; Chamberlain JS; Rafael-Fortney JA
JCI Insight; 2021 Apr; 6(7):. PubMed ID: 33651713
[TBL] [Abstract][Full Text] [Related]
8. Cardiac Management of the Patient With Duchenne Muscular Dystrophy.
Buddhe S; Cripe L; Friedland-Little J; Kertesz N; Eghtesady P; Finder J; Hor K; Judge DP; Kinnett K; McNally EM; Raman S; Thompson WR; Wagner KR; Olson AK
Pediatrics; 2018 Oct; 142(Suppl 2):S72-S81. PubMed ID: 30275251
[TBL] [Abstract][Full Text] [Related]
9. Cardiac Involvement Classification and Therapeutic Management in Patients with Duchenne Muscular Dystrophy.
Fayssoil A; Abasse S; Silverston K
J Neuromuscul Dis; 2017; 4(1):17-23. PubMed ID: 28269790
[TBL] [Abstract][Full Text] [Related]
10. Na
Bkaily G; Jacques D
Can J Physiol Pharmacol; 2017 Oct; 95(10):1213-1223. PubMed ID: 28727929
[TBL] [Abstract][Full Text] [Related]
11. Angiotensin-converting enzyme inhibitors and beta-blockers in cardiac asymptomatic patients with Duchenne muscular dystrophy.
Fayssoil A
Indian Heart J; 2010; 62(3):273. PubMed ID: 21275309
[TBL] [Abstract][Full Text] [Related]
12. Cardiac monitoring and treatment for children and adolescents with neuromuscular disorders.
Bourke JP
Dev Med Child Neurol; 2006 Mar; 48(3):164. PubMed ID: 16483389
[No Abstract] [Full Text] [Related]
13. New approaches in the therapy of cardiomyopathy in muscular dystrophy.
McNally EM
Annu Rev Med; 2007; 58():75-88. PubMed ID: 17217326
[TBL] [Abstract][Full Text] [Related]
14. Cardiac Pathophysiology and the Future of Cardiac Therapies in Duchenne Muscular Dystrophy.
Meyers TA; Townsend D
Int J Mol Sci; 2019 Aug; 20(17):. PubMed ID: 31443395
[TBL] [Abstract][Full Text] [Related]
15. Cardiac management of ventilator-assisted individuals with Duchenne muscular dystrophy.
O'Brien L; Varadi R; Goldstein RS; Evans RA
Chron Respir Dis; 2014 May; 11(2):103-10. PubMed ID: 24728656
[TBL] [Abstract][Full Text] [Related]
16. Clinical Manifestations and Overall Management Strategies for Duchenne Muscular Dystrophy.
Tsuda T
Methods Mol Biol; 2018; 1687():19-28. PubMed ID: 29067653
[TBL] [Abstract][Full Text] [Related]
17. Effects of angiotensin-converting enzyme inhibitors and/or beta blockers on the cardiomyopathy in Duchenne muscular dystrophy.
Viollet L; Thrush PT; Flanigan KM; Mendell JR; Allen HD
Am J Cardiol; 2012 Jul; 110(1):98-102. PubMed ID: 22463839
[TBL] [Abstract][Full Text] [Related]
18. Randomised placebo-controlled trial of combination ACE inhibitor and beta-blocker therapy to prevent cardiomyopathy in children with Duchenne muscular dystrophy? (DMD Heart Protection Study): a protocol study.
Bourke JP; Watson G; Muntoni F; Spinty S; Roper H; Guglieri M; Speed C; McColl E; Chikermane A; Jayawant S; Adwani S; Willis T; Wilkinson J; Bryant A; Chadwick T; Wood R; Bushby K;
BMJ Open; 2018 Dec; 8(12):e022572. PubMed ID: 30573480
[TBL] [Abstract][Full Text] [Related]
19. Long-term improvement in mdx cardiomyopathy after therapy with peptide-conjugated morpholino oligomers.
Jearawiriyapaisarn N; Moulton HM; Sazani P; Kole R; Willis MS
Cardiovasc Res; 2010 Feb; 85(3):444-53. PubMed ID: 19815563
[TBL] [Abstract][Full Text] [Related]
20. Exosome-Derived Dystrophin from Allograft Myogenic Progenitors Improves Cardiac Function in Duchenne Muscular Dystrophic Mice.
Su X; Jin Y; Shen Y; Ju C; Cai J; Liu Y; Kim IM; Wang Y; Yu H; Weintraub NL; Jiang M; Tang Y
J Cardiovasc Transl Res; 2018 Oct; 11(5):412-419. PubMed ID: 30155598
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
